Literature DB >> 11682028

Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances.

L Albornoz1, A Motta, D Alvarez, A Estevez, J C Bandi, L McCormack, J Matera, C Bonofiglio, M Ciardullo, E De Santibañes, M Gimeno, A Gadan.   

Abstract

BACKGROUND/AIMS: It has been demonstrated that an overproduction of nitric oxide plays an important role in the pathogenesis of the hyperdynamic circulation exhibited by cirrhotic patients. Nevertheless, evidence is supported by studies performed in experimental models or by indirect measurements in humans. The purpose of this study has been to evaluate nitric oxide production in splanchnic vasculature of patients with cirrhosis and to investigate its possible relationship with systemic and splanchnic hemodynamics.
METHODS: Nitric oxide synthase (NOS) activity was measured in hepatic artery and portal vein tissues of nine cirrhotic patients. Samples were obtained during liver transplantation. Control samples were obtained simultaneously from the corresponding tissues of the liver donors. Hemodynamic parameters were determined with Doppler ultrasonography.
RESULTS: NOS activity was significantly higher in hepatic artery of cirrhotic patients than in controls (8.17 +/- 1.30 vs 4.57 +/- 0.61 pmoles/g of tissue/min, P < 0.05). Patients with ascites showed a higher hepatic artery NOS activity than patients without ascites. Highly significant correlation was observed between cardiac output and hepatic artery NOS activity as well as between portal blood flow and hepatic artery NOS activity.
CONCLUSIONS: The present study demonstrates an enhanced production of nitric oxide in the splanchnic vasculature of patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682028     DOI: 10.1016/s0168-8278(01)00168-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 2.  Cirrhotic cardiomyopathy: a cardiologist's perspective.

Authors:  Natig Gassanov; Evren Caglayan; Nasser Semmo; Gero Massenkeil; Fikret Er
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension.

Authors:  Lukas Moleda; Lars Jurzik; Matthias Froh; Erwin Gäbele; Claus Hellerbrand; Rainer H Straub; Jürgen Schölmerich; Reiner Wiest
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

Review 4.  Nitric oxide and portal hypertension.

Authors:  Juan González-Abraldes; Juan Carlos García-Pagán; Jaime Bosch
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

5.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

6.  Effect of biliary cirrhosis on neurogenic relaxation of rat gastric fundus and anococcygeus muscle: role of nitric oxide pathway.

Authors:  Mehdi Ghasemi; Ali Reza Karimollah; Bardia Bakhtiari; Abbas Ghasemi; Leila Moezi; Arash Bahremand; Pouya Ziaei; Ahmad Reza Dehpour
Journal:  Dig Dis Sci       Date:  2014-06-05       Impact factor: 3.199

7.  Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites.

Authors:  J Genescà; R Martí; F Rojo; F Campos; V Peribáñez; A Gónzalez; L Castells; C Ruiz-Marcellán; C Margarit; R Esteban; J Guardia; R Segura
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

Review 8.  Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.

Authors:  Kwang Yong Shim; Young Woo Eom; Moon Young Kim; Seong Hee Kang; Soon Koo Baik
Journal:  Korean J Intern Med       Date:  2018-02-21       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.